
-
Y-mAbs Therapeutics NasdaqGS:YMAB Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Location: 202 Carnegie Center, Princeton, NJ, 08540, United States | Website: https://www.ymabs.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
155.4M
Cash
60.31M
Avg Qtr Burn
-4.787M
Short % of Float
11.24%
Insider Ownership
11.50%
Institutional Own.
70.98%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DANYELZA® (naxitamab-gqgk) Details Spinal cord tumor, Neuroblastoma, Spinal cord injury, Cancer, Osteosarcoma | Approved Quarterly sales | |
DANYELZA® (naxitamab-gqgk) Details Cancer, Osteosarcoma | Phase 2 Update | |
DANYELZA® (naxitamab-gqgk) Details Neuroblastoma, Cancer | Phase 2 Update | |
CD38-SADA Details Cancer, Non-Hodgkin lymphoma | Phase 1 Data readout | |
GD2-SADA Details Melanoma, Small cell lung cancer, Sarcoma, Neuroblastoma | Phase 1 Data readout | |
SADA Details Cancer, Neuroblastoma | IND Submission | |
GD2-GD3 Vaccine Details Rare diseases, Spinal cord tumor, Neuroblastoma, Cancer | Failed Discontinued | |
Omburtamab (monoclonal antibody 8H9 (131I-8H9)) Details Brain tumor, Spinal cord tumor | Failed Discontinued |